[Effectiveness and safety of brolucizumab in the treatment of neovascular age-related macular degeneration].

Q3 Medicine

Vestnik oftalmologii Pub Date : 2024-01-01 DOI:10.17116/oftalma202414004140

A N Kulikov, V R Zhalimova, N A Nekrash, Y A Kalinicheva, A S Vasilyev, D S Maltsev

{"title":"[Effectiveness and safety of brolucizumab in the treatment of neovascular age-related macular degeneration].","authors":"A N Kulikov, V R Zhalimova, N A Nekrash, Y A Kalinicheva, A S Vasilyev, D S Maltsev","doi":"10.17116/oftalma202414004140","DOIUrl":null,"url":null,"abstract":"Purpose: This study analyzes the effectiveness and safety of brolucizumab in the treatment of neovascular age-related macular degeneration (nAMD) in real clinical practice.Material and methods: The study included patients with nAMD who received brolucizumab treatment and evaluated the changes in best-corrected visual acuity (BCVA), central retinal thickness (CRT), macular volume, as well as the number of injections and adverse events.Result: The group of previously treated patients included 28 subjects (28 eyes) that were switched to brolucizumab with a loading phase. By 12 months, BCVA changed from 0.43±0.29 to 0.33±0.27 LogMAR (p=0.11), CRT decreased from 281.5±58.2 to 239.9±45.6 µm (p=0.02). The group of previously untreated patients included 29 subjects (29 eyes). By 12 months, BCVA changed from 0.47±0.32 to 0.40±0.30 LogMAR (p=0.09), CRT decreased from 333.2±77.3 to 226.2±49.6 µm (p<0.001). Patients received 6.3±0.7 injections. In this group, baseline choroidal thickness showed a statistically significant correlation with final visual acuity (r=0.54; p<0.05) and CRT (r= -0.5; p<0.05). The group of previously treated patients switched without a loading phase included 18 patients (18 eyes). By 6 months, BCVA changed from 0.42±0.2 to 0.37±0.26 LogMAR (p=0.42). CRT remained stable at 285.6±56.9 µm (p=0.97). No adverse events related to intraocular inflammation were reported during the course of 385 injections.Conclusion: Brolucizumab therapy helps achieve significant anatomical and functional improvements in real clinical practice both in patients switched from previous treatments and in treatment-naïve patients. Greater baseline choroidal thickness may be associated with better anatomical and functional outcomes with brolucizumab treatment.","PeriodicalId":23529,"journal":{"name":"Vestnik oftalmologii","volume":"140 4","pages":"40-48"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vestnik oftalmologii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.17116/oftalma202414004140","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: This study analyzes the effectiveness and safety of brolucizumab in the treatment of neovascular age-related macular degeneration (nAMD) in real clinical practice.

Material and methods: The study included patients with nAMD who received brolucizumab treatment and evaluated the changes in best-corrected visual acuity (BCVA), central retinal thickness (CRT), macular volume, as well as the number of injections and adverse events.

Result: The group of previously treated patients included 28 subjects (28 eyes) that were switched to brolucizumab with a loading phase. By 12 months, BCVA changed from 0.43±0.29 to 0.33±0.27 LogMAR (p=0.11), CRT decreased from 281.5±58.2 to 239.9±45.6 µm (p=0.02). The group of previously untreated patients included 29 subjects (29 eyes). By 12 months, BCVA changed from 0.47±0.32 to 0.40±0.30 LogMAR (p=0.09), CRT decreased from 333.2±77.3 to 226.2±49.6 µm (p<0.001). Patients received 6.3±0.7 injections. In this group, baseline choroidal thickness showed a statistically significant correlation with final visual acuity (r=0.54; p<0.05) and CRT (r= -0.5; p<0.05). The group of previously treated patients switched without a loading phase included 18 patients (18 eyes). By 6 months, BCVA changed from 0.42±0.2 to 0.37±0.26 LogMAR (p=0.42). CRT remained stable at 285.6±56.9 µm (p=0.97). No adverse events related to intraocular inflammation were reported during the course of 385 injections.

Conclusion: Brolucizumab therapy helps achieve significant anatomical and functional improvements in real clinical practice both in patients switched from previous treatments and in treatment-naïve patients. Greater baseline choroidal thickness may be associated with better anatomical and functional outcomes with brolucizumab treatment.

查看原文本刊更多论文

[肉毒杆菌治疗新生血管性老年黄斑变性的有效性和安全性]。

目的：本研究分析了在实际临床实践中布卢单抗治疗新生血管性年龄相关性黄斑变性（nAMD）的有效性和安全性：研究纳入了接受过布卢单抗治疗的nAMD患者，评估了最佳矫正视力（BCVA）、视网膜中央厚度（CRT）、黄斑体积的变化以及注射次数和不良反应：结果：先前接受过治疗的患者中有28名受试者（28只眼）在负荷期改用了brolucizumab。12个月后，BCVA从0.43±0.29 LogMAR变为0.33±0.27 LogMAR（P=0.11），CRT从281.5±58.2 µm变为239.9±45.6 µm（P=0.02）。之前未接受治疗的患者组包括 29 名受试者（29 只眼）。12个月后，BCVA从0.47±0.32 LogMAR变为0.40±0.30 LogMAR（p=0.09），CRT从333.2±77.3 µm变为226.2±49.6 µm（pr=0.54；pr= -0.5；pp=0.42）。CRT稳定在285.6±56.9 µm（P=0.97）。在385次注射过程中，未报告与眼内炎症相关的不良事件：结论：在实际临床实践中，无论是对以前接受过治疗的患者，还是对未接受过治疗的患者，布卢珠单抗疗法都有助于在解剖学和功能方面取得显著改善。基线脉络膜厚度越大，博路单抗治疗的解剖和功能效果越好。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Vestnik oftalmologii Medicine-Ophthalmology

CiteScore

0.80

自引率

0.00%

发文量

129

期刊介绍： The journal publishes materials on the diagnosis and treatment of eye diseases, hygiene of vision, prevention of ophthalmic affections, history of Russian ophthalmology, organization of ophthalmological aid to the population, as well as the problems of special equipment. Original scientific articles and surveys on urgent problems of theory and practice of Russian and foreign ophthalmology are published. The journal contains book reviews on ophthalmology, information on the activities of ophthalmologists" scientific societies, chronicle of congresses and conferences.The journal is intended for ophthalmologists and scientific workers dealing with clinical problems of diseases of the eye and physiology of vision.